The research revealed that ARHGAP39 expression was positively related to CTLA-4, PDCD1, CCR8, HAVCR2, TGFB1, and STAT5B, bringing new hope for the precise treatment of HCC with immune checkpoint inhibitors (ICI). Here, ARHGAP39 is linked to hepatocellular carcinoma.